Novartis to buy radiology drug specialist Mariana for $1 billion
Adds details on technology in paragraphs 5 and 6
By Andrey Sychev and Ludwig Burger
May 2 (Reuters) -Novartis NOVN.S agreed to acquire U.S. radiopharmaceutical company Mariana Oncology for $1 billion upfront, boosting its portfolio of precision cancer treatments in development, the Swiss drug manufacturer said on Thursday.
The deal includes up to $750 million of further payments upon achieving certain milestones, it added.
Mariana Oncology is working on novel radioligand cancer therapies (RLTs) that have not yet been tested on humans.
"The transaction bolsters the Novartis RLT pipeline and expands the company’s research infrastructure and clinical supply capabilities," Novartis said in a statement.
Radioligand therapy, based on cell-killing radioactive particles that are attached to tumour-seeking molecules, is one of three technologies that Novartis' development efforts are focused on, apart from cell and gene therapy as well as RNA.
The Swiss group's radioligand drugs include Pluvicto against prostate cancer and Lutathera against a rare group of gastrointestinal tumours.
Novartis has been cutting jobs and costs, and spun off its generic drugs business Sandoz last year, part of a focus on fewer therapeutic areas and geographic markets.
In February, it struck a deal to buy German cancer drug developer MorphoSys MORG.DE for 2.7 billion euros ($2.89 billion).
($1 = 0.9348 euros)
Additional reporting by Paul Arnold,
editing by Matthias Williams and Elaine Hardcastle
Related Assets
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
